Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
 Securities Case - EconoTimes)
NEW YORK, Dec. 05, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 3, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ:CEMP). The class action is on behalf of a class consisting of all persons who purchased or otherwise acquired Cempra securities between May 1, 2016 and November 1, 2016, both dates inclusive (the “Class Period”). Cempra investors are encouraged to go to: https://www.scott-scott.com/cases/new/securities-fraud-litigation-3029-cempra-inc-cemp.html.
Cempra is a clinical-stage pharmaceutical company, that focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. One of its lead product candidates is solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra’ public statements were materially false and misleading at all relevant times.
On November 2, 2016, the United States Food and Drug Administration (“FDA”) posted on its website a preliminary review of solithromycin in which it indicated that the drug can lead to an elevation in liver enzyme levels and other potential causes of hepatotoxicity. On this news, Cempra’s share price fell over 60%.
What You Can Do
If you purchased Cempra shares, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Halloran at (646) 582-0121, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joseph Halloran Scott+Scott, Attorneys at Law, LLP (646) 582-0121 [email protected]
